{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:41:56Z","timestamp":1777329716312,"version":"3.51.4"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tuberous sclerosis complex (TSC) is an autosomal-dominant multi system disorder. The genetic basis of the disorder is mutations in the\n                    <jats:italic>TSC1<\/jats:italic>\n                    or\n                    <jats:italic>TSC2<\/jats:italic>\n                    gene, which leads to over activation of the mammalian target of rapamycin (mTOR) protein complex and results in development of benign tumors in different body systems such as brain, skin, lungs and kidney. The mTOR inhibitors are presently the main treatment option for patients with TSC. We here report a 21-year female patient with large bilateral angiomyolipoma (AML) in both kidneys with longest diameter more than 12.3 cm and subependymal giant cell astrocytoma (SEGA). Treatment with everolimus (EVE) was initiated at a dose of 10.0 mg\/day and continued during the following 3 years. Magnetic resonance imaging (MRI) was performed before treatment with everolimus was initiated, and consequently at 12 and 36 months for follow-up of the efficacy of the treatment. After 3 years, the total size of largest AML decreased by ~24.0% in the longest diameter. A reduction of the total size of SEGA was also observed. The most common adverse effect of treatment was stomatitis grades 3 to 4 and one febrile episode associated with skin rash that required a reduced dose of EVE. In conclusion, the everolimus treatment improved even such a large renal AML and the effect persisted during the long-term administration with a small number of adverse effects. A positive effect was observed on the brain tumor as well.\n                  <\/jats:p>","DOI":"10.2478\/bjmg-2020-0017","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T18:02:49Z","timestamp":1617732169000},"page":"93-98","source":"Crossref","is-referenced-by-count":2,"title":["Bilateral renal angiomyolipomas and subependymal giant cell astrocytoma associated with tuberous sclerosis complex: A case report and review of the literature"],"prefix":"10.2478","volume":"23","author":[{"given":"I","family":"Rambabova Bushljetik","sequence":"first","affiliation":[{"name":"University Clinic of Nephrology , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lazareska","sequence":"additional","affiliation":[{"name":"Institute of Radiology , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Barbov","sequence":"additional","affiliation":[{"name":"University Clinic of Neurology , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Stankov","sequence":"additional","affiliation":[{"name":"University Clinic of Urology , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Filipce","sequence":"additional","affiliation":[{"name":"University Clinic of Neurosurgery , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Spasovski","sequence":"additional","affiliation":[{"name":"University Clinic of Nephrology , Skopje , Republic of North Macedonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"2026042718393658423_j_bjmg-2020-0017_ref_001_w2aab3b7b3b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"O\u2019Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998; 351(9114): 1490.","DOI":"10.1016\/S0140-6736(05)78872-3"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_002_w2aab3b7b3b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006; 355(13): 1345-1356.","DOI":"10.1056\/NEJMra055323"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_003_w2aab3b7b3b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Jansen FE, van Nieuwenhuizen O, van Huffelen AC. Tuberous sclerosis complex and its founders. J Neurol Neurosurg Psychiatry. 2004; 75(5): 770.","DOI":"10.1136\/jnnp.2003.027524"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_004_w2aab3b7b3b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Brigo F, Lattanzi S, Trinka E, Nardone R, Bragazzi NL, Ruggieri M, et al. First descriptions of tuberous sclerosis by D\u00e9sir\u00e9-Magloire Bourneville (18401909. Neuro-pathology. 2018; 38(6):577-582.","DOI":"10.1111\/neup.12515"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_005_w2aab3b7b3b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Rodrigues DA, Gomes CM, Costa IM. Tuberous sclerosis complex. Ann Bras Dermatol. 2012; 87(2): 184-196.","DOI":"10.1590\/S0365-05962012000200001"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_006_w2aab3b7b3b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Portocarrero LKL, Quental KN, Samorano LP, de Oliveira ZNP, Rivitti-Machado MCDM. Tuberous sclerosis complex: review based on new diagnostic criteria. Ann Bras Dermatol. 2018; 93(3): 323-331.","DOI":"10.1590\/abd1806-4841.20186972"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_007_w2aab3b7b3b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Pirson Y. Tuberous sclerosis complex-associated kidney angiomyolipoma: From contemplation to action. Nephrol Dial Transplant. 2013; 28(7): 1680-1685.","DOI":"10.1093\/ndt\/gft009"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_008_w2aab3b7b3b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol. 1998; 13(12): 624-628.","DOI":"10.1177\/088307389801301206"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_009_w2aab3b7b3b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013; 49(4): 243-254.","DOI":"10.1016\/j.pediatrneurol.2013.08.001"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_010_w2aab3b7b3b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Gabardi S, Baroletti SA Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharma-cotherapy. 2010; 30(10): 1044-1056.","DOI":"10.1592\/phco.30.10.1044"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_011_w2aab3b7b3b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Capal JK, Franz DN. Profile of everolimus in the treatment of tuberous sclerosis complex: An evidence-based review of its place in therapy. Neuropsychiatr Dis Treat. 2016; 12: 2165-2172.","DOI":"10.2147\/NDT.S91248"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_012_w2aab3b7b3b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015; 14(7): 733-745.","DOI":"10.1016\/S1474-4422(15)00069-1"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_013_w2aab3b7b3b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Budde K, Gaedeke J. Tuberous sclerosis complex-associated angiomyolipomas: Focus on mTOR inhibition. Am J Kidney Dis. 2012; 59(2): 276-283.","DOI":"10.1053\/j.ajkd.2011.10.013"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_014_w2aab3b7b3b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17): 1595-1606.","DOI":"10.1056\/NEJMoa1100391"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_015_w2aab3b7b3b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Jacks SK, Witman PM. Tuberous sclerosis complex: An update for dermatologists. Pediatr Dermatol. 2015; 32(5): 563-570.","DOI":"10.1111\/pde.12567"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_016_w2aab3b7b3b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Murray TE, Doyle F, Lee M. Transarterial embolization of angiomyolipoma: A systematic review. J Urol. 2015; 194(3): 635-639.","DOI":"10.1016\/j.juro.2015.04.081"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_017_w2aab3b7b3b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013; 381(9861): 125-132.","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_018_w2aab3b7b3b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebocontrolled trial. Lancet. 2013; 381(9869): 817-824.","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_019_w2aab3b7b3b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One. 2017; 12(8): e0180939.","DOI":"10.1371\/journal.pone.0180939"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_020_w2aab3b7b3b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Toriu N, Mizuno H, Sawa N, Sumida K, Suwabe T, Hayami N, et al. Everolimus reduces the size of tuberous sclerosis complex-related huge renal angiomyolipomas exceeding 20 cm in the longest diameter. Case Rep Oncol. 2018; 11(2): 258-267.","DOI":"10.1159\/000488704"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_021_w2aab3b7b3b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz P, Drabik K, et al., Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 2014; 50(4): 307\u2013312.","DOI":"10.1016\/j.pediatrneurol.2013.12.004"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_022_w2aab3b7b3b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Roth J, Roach ES, Bartels U, J\u00f3\u017awiak S, Koenig MK, Weiner HL, et al.. Subependymal giant cell astrocytoma: Diagnosis, screening, and treatment. Recommendations from the International Tuberous sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013; 49(6): 439-444.","DOI":"10.1016\/j.pediatrneurol.2013.08.017"},{"key":"2026042718393658423_j_bjmg-2020-0017_ref_023_w2aab3b7b3b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Stein JR, Reidman DA. Imaging manifestations of a subependymal giant cell astrocytoma in tuberous sclerosis. Case Rep Radiol. 2016; 2016: 3750450.","DOI":"10.1155\/2016\/3750450"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/bjmg-2020-0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:05:07Z","timestamp":1777327507000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/bjmg-2020-0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,3,23]]},"published-print":{"date-parts":[[2021,3,23]]}},"alternative-id":["10.2478\/bjmg-2020-0017"],"URL":"https:\/\/doi.org\/10.2478\/bjmg-2020-0017","relation":{},"ISSN":["1311-0160"],"issn-type":[{"value":"1311-0160","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}